Auris Medical (NASDAQ:EARS) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday.
According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
Other equities analysts also recently issued reports about the company. ValuEngine upgraded Auris Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Roth Capital started coverage on Auris Medical in a research report on Thursday, December 20th. They issued a “buy” rating and a $5.00 price objective on the stock.
Auris Medical (NASDAQ:EARS) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01).
About Auris Medical
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.